MedTrace Logo

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

NCT00500370 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2015-04-07

Study results available
· View outcomes & findings →

Summary

This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.

Conditions

Interventions

DRUG

exenatide

subcutaneous injection (5mcg or 10mcg), twice a day

DRUG

placebo

subcutaneous injection (equivalent volume to active dose), twice a day

Sponsors & Collaborators

Principal Investigators

  • James Malone, MD · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500370 on ClinicalTrials.gov